Loading...

Centene desmopressin coverage update Prior Auth | OpenPayer

CurrentCentenePolicy CP.PHAR.214

Clinical Policy: Desmopressin Acetate (DDAVP, Desmoda, Stimate, Nocdurna)

Covers clinical medical necessity and prior authorization criteria for desmopressin products (injectable, intranasal, tablet, branded formulations) across Centene lines of business for specified indications including central diabetes insipidus, nocturia, hemophilia A, and von Willebrand disease.

Policy Summary

PayerCentene

PolicyDesmopressin Acetate (DDAVP, Desmoda, Stimate, Nocdurna)

Policy CodePolicy CP.PHAR.214

Change TypeAdded product, revised durations, IL step therapy bypass

Effective Date05.01.16

Next Review Date

Key ActionProvider must submit documentation (office chart notes, lab results, or other clinical information) showing the member meets all approval criteria and obtain prior authorization.

SourceLink

POLICY UPDATE CHANGES

Added new oral solution Desmoda to policy.

Revised initial approval durations: hemophilia/VWD surgical/acute bleeding to 3 months and Medicaid/HIM initial approval durations for other indications from 6 to 12 months.

Added step therapy bypass for IL HIM per IL HB 5395.

Added generic versions of DDAVP and Stimate to clarify criteria applicability and redirection to generic desmopressin injection for brand DDAVP injection requests.

4major indication sections

12Medicaid/HIM approval duration

≥18Nocdurna minimum age

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria

Initial Therapy — Polyuria/Central DI

Covered when ALL of the following are met

Polyuria and Central DI initial criteria: 1) Request is for one of the following: a) DDAVP injection; or b) Desmoda; 2) Diagnosis of one of the following: a) central (cranial) diabetes insipidus (arginine vasopressin deficiency) for any agent; or b) for DDAVP injection only, temporary polyuria and polydipsia following head trauma or surgery in the pituitary region; 3) Prescribed by or in consultation with an endocrinologist; 4) For DDAVP: Age ≥ 12 years; 5) Failure of desmopressin tablets unless contraindicated, clinically significant adverse effects occur, or documentation supports inability to swallow tablets (Illinois HIM requests are exempt from this step therapy requirement effective 1/1/2026); 6) For brand DDAVP injection requests, member must use desmopressin injection unless contraindicated or clinically significant adverse effects are experienced; 7) Dose does not exceed one of the following: a) DDAVP: 4 mcg per day; b) Desmoda: 5 bottles per month.see dose limits

Approval durations vary by line of business

Initial Therapy — Hemophilia A

Covered when ALL of the following are met

Hemophilia A initial criteria: 1) Diagnosis of congenital hemophilia A (factor VIII deficiency); 2) Prescribed by or in consultation with a hematologist; 3) Age ≥ 3 months; 4) Request is for DDAVP injection or Stimate for one of the following: a) control and prevention of bleeding episodes; b) perioperative management; c) routine prophylaxis to prevent or reduce frequency of bleeding episodes; 5) Factor VIII coagulant activity level > 5%; 6) Member does not have factor VIII antibodies; 7) For brand DDAVP injection requests, member must use desmopressin injection unless contraindicated or clinically significant adverse effects are experienced; 8) Dose does not exceed one of the following: a) DDAVP injection: 0.3 mcg/kg per dose; b) Stimate: 300 mcg per day.FVIII > 5% and dose limits

Surgical/acute bleeding approval duration: 3 months; prophylaxis durations vary by line of business

Initial Therapy — Von Willebrand Disease

Covered when ALL of the following are met

VWD initial criteria: 1) Diagnosis of von Willebrand disease type 1 or type 2; 2) Prescribed by or in consultation with a hematologist; 3) Age ≥ 3 months; 4) Request is for DDAVP injection or Stimate for one of the following: a) control and prevention of bleeding episodes; b) perioperative management; c) routine prophylaxis to prevent or reduce frequency of bleeding episodes; 5) Factor VIII coagulant activity level > 5%; 6) For brand DDAVP injection requests, member must use desmopressin injection unless contraindicated or clinically significant adverse effects are experienced; 7) Dose does not exceed one of the following: a) DDAVP injection: 0.3 mcg/kg per dose; b) Stimate: 300 mcg per day.FVIII > 5% and dose limits

Surgical/acute bleeding approval duration: 3 months; prophylaxis durations vary by line of business

Initial Therapy — Nocturia

Covered when ALL of the following are met

Nocturia initial criteria: 1) Diagnosis of nocturia due to nocturnal polyuria; 2) Age ≥ 18 years; 3) Request is for Nocdurna (desmopressin sublingual tablet); 4) Dose does not exceed 1 tablet per day and one of the following: a) 27.7 mcg for women; b) 55.3 mcg for men.dose by sex

Approval duration: 12 months

Continued Therapy — Criteria for continuation of therapy

Covered when ALL of the following are met

Continued therapy criteria: 1) Member meets one of the following: a) currently receiving medication via Centene benefit or previously met initial approval criteria; or b) member is receiving medication and is enrolled in a state/product with continuity of care regulations; 2) Member is responding positively to therapy; 3) For brand DDAVP injection requests, member must use desmopressin injection unless contraindicated or clinically significant adverse effects are experienced; 4) If request is for a dose increase, the new dose does not exceed one of the following: a) DDAVP injection: 4 mcg per day for polyuria/DI or 0.3 mcg/kg per dose for hemophilia A or VWD; b) Desmoda: 5 bottles per month; c) Stimate: 300 mcg per day; d) Nocdurna: 1 tablet per day — 27.7 mcg for women or 55.3 mcg for men.

Approval durations by line of business specified

General routing and indication references

Coverage applies when applicable indication-specific criteria (present elsewhere in policy) are met; see off-label and formulary routing when recent label changes or non-listed uses occur.

Label change routing: If this drug has undergone a label change within the last 6 months that is not yet reflected in this policy, refer to the applicable formulary or non-formulary policy for the line of business as specified in the policy.

See CP.CPA.190, HIM.PA.33, CP.PMN.255 for formulary routing or HIM.PA.103, CP.PMN.16 for non-formulary routing

Non-FDA indications: Non‑FDA approved indications not addressed in this policy require sufficient documentation of efficacy and safety per the off‑label use policies to be considered for coverage; otherwise such uses are not authorized.

See CP.CPA.09, HIM.PA.154, CP.PMN.53

Indication-specific dosing: Dosing and maximum doses vary by product and indication; approvals assume adherence to indicated dosing ranges and maximums.

Examples include DDAVP injection maximum 4 mcg/day (polyuria/DI) and Nocdurna 27.7 mcg (women) or 55.3 mcg (men) QD prior to bedtime.

Desmopressin products (including DDAVP and Desmoda) are not indicated for nephrogenic diabetes insipidus. Clinical evidence and product limitations state that DDAVP and Desmoda are ineffective for nephrogenic DI; requests for desmopressin to treat nephrogenic DI should be denied as not medically necessary.

Requests for uses that are not FDA‑approved and not addressed in this policy are excluded from coverage unless the provider submits sufficient supporting documentation of efficacy and safety as required by the applicable off‑label use policies (see CP.CPA.09 for commercial, HIM.PA.154 for marketplace, CP.PMN.53 for Medicaid) or other evidence of coverage. Absent that documentation, non‑FDA indications will be denied.

There are specific limitations of use for desmopressin formulations: Stimate is not indicated for hemophilia A with FVIII activity ≤ 5%, for hemophilia B, or for patients with FVIII antibodies. Additionally, DDAVP and Stimate are not indicated for severe classic von Willebrand disease (type I) when an abnormal molecular form of FVIII antigen is present. These scenarios should be considered not medically necessary for DDAVP or Stimate therapy.

Non‑FDA uses of desmopressin that lack sufficient documentation per the off‑label use policies or evidence of coverage are not authorized. Providers must supply chart notes, laboratory results, or other clinical information demonstrating efficacy and safety in accordance with the referenced off‑label policies; otherwise the request will be considered not covered.

Coding and Dosing Limits

HCPCS CodesHCPCS

J2597

Injection, desmopressin acetate, per 1 mcg

Dose limits — desmopressin products

DDAVP (injection) — polyuria/DIMaximum 4 mcg per day (2–4 mcg IV/SC daily, one or two divided doses)

DDAVP (injection) — hemophilia A / VWD0.3 mcg/kg per dose (maximum per dose for these indications)

Desmoda (oral solution)Maximum: limit referenced to dosing regimen (initial 0.05 mg PO BID; titrate to response); policy caps at 5 bottles per month for approval criteria

Stimate (nasal spray)Maximum 300 mcg per day (one spray per nostril dosing regimen for hemostatic indications)

Nocdurna (sublingual tablet)Maximum 1 tablet per day — women 27.7 mcg/day; men 55.3 mcg/day

Maximum doses for Nocdurna (sex-specific)

Provider Actions and Authorization Requirements

Prior Authorization

Prior Authorization Required

Prior Authorization Required: Prior authorization is required for DDAVP injection, Desmoda, Stimate, and Nocdurna. Provider must submit clinical documentation (e.g., office notes, lab results, operative reports) supporting that the member meets all applicable approval criteria.

Affects DDAVP injection, Desmoda, Stimate, Nocdurna
Provider documentation: office chart notes, labs, other clinical information

Step Therapy

Step Therapy — Tablets Prior to Injection

Step therapy: tablets before injection — requests for DDAVP injection generally require documented failure of desmopressin tablets (or clinical contraindication, significant adverse effects, or inability to swallow tablets) prior to approval of injectable desmopressin. For Illinois HIM requests, the step therapy requirement does not apply beginning 01/01/2026 per IL HB 5395.

Failure of desmopressin tablets required unless contraindicated, significant adverse effects, or inability to swallow tablets

Background

Desmopressin acetate is a synthetic vasopressin analogue available in multiple formulations (injectable DDAVP, oral solution Desmoda, intranasal, sublingual tablet Stimate, and oral tablet Nocdurna) and is indicated for select conditions. Indications include central (cranial) diabetes insipidus and temporary polyuria after pituitary surgery or head trauma (treated with DDAVP injection or appropriate formulations), and select bleeding disorders such as mild to moderate von Willebrand disease (type 1) and certain cases of hemophilia A with adequate FVIII activity. Nocdurna (desmopressin tablet) is indicated for nocturia due to nocturnal polyuria in adults and has sex‑specific dosing limits. Certain formulations (DDAVP and Desmoda) are ineffective for nephrogenic diabetes insipidus, and other limitations of use apply (for example, Stimate is not indicated for hemophilia B or hemophilia A with FVIII ≤ 5% or FVIII antibodies).

Definitions

Central (cranial) diabetes insipidus — definition and clinical context

DefinitionCentral (cranial) diabetes insipidus: deficiency of arginine vasopressin managed with desmopressin formulations; includes temporary post‑pituitary surgery or head trauma cases

Typical managementTreated with desmopressin formulations (DDAVP injection, Desmoda oral solution, or other desmopressin products) as antidiuretic replacement therapy

Prescribing considerationsRequests require endocrinologist prescribing/consultation and adherence to formulation-specific dosing limits

Nocturnal polyuria / Nocturia — definition and Nocdurna note

DefinitionNocturia due to nocturnal polyuria: night‑time urine overproduction causing the patient to awaken at least 2 times per night to void

Nocdurna indication